Skip to main content
Meet Steve and Diana, a story of confidence and strength

A diagnosis of advanced prostate cancer is life-changing. Steve and his wife, Diana, share their story, beginning with Steve’s surprise diagnosis with prostate cancer at age 50. Learn how Steve found his voice in patient advocacy after years of stage fright*.


*Patient experiences are individual and vary. Steve and Diana have been compensated by Novartis for their participation in this video.

Meet Van, a patient with PSMA+ mCRPC

Sometimes it helps to know what the PLUVICTO process was like for other patients.* Watch Van talk about his PLUVICTO journey.

*Patient experiences are individual and vary. Van has been compensated by Novartis for his participation in this video.

See what's behind the making of PLUVICTO

A lot goes into PLUVICTO before it gets to you. The manufacturing process is a race against the clock. Take a peek at this behind-the-scenes video about the making of PLUVICTO to understand more about why Novartis is committed to discovering and developing treatments like PLUVICTO for patients like you.

Understanding treatment with PLUVICTO

Knowing what to expect in your treatment with PLUVICTO may help you and your family be prepared and empowered to ask your doctor any questions you may have. For a written overview about the experience with each step of the PLUVICTO process, go to What to Expect When Taking PLUVICTO.

mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.

Important Safety Information

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer...

Approved Use

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen­–­positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...